X

Trial Profile

An Open-label Early Access Phase IIIb Study of Trifluridine / Tipiracil (S 95005/TAS-102) in Patients With a Pretreated Metastatic Colorectal Cancer (PRECONNECT)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 14 Feb 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tipiracil/trifluridine (Primary)
Indications Adenocarcinoma; Colorectal cancer
Focus Adverse reactions; Expanded access; Registrational
Acronyms PRECONNECT
Sponsors Servier

Most Recent Events

27 Jan 2023 Results assessing safety and efficacy of trifluridine/tipiracil (FTD/TPI) for metastatic colorectal cancer published in the BMC Cancer
03 Jul 2021 Final results from PRECONNECT according to duration of treatment, presented at the 23rd World Congress on Gastrointestinal Cancer
07 Dec 2020 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com